CAM use – the providers’ perspective
In Europe, CAM treatments are provided by a large number of physicians, but in some countries also by non medical therapists, and in some countries almost exclusively by non-academic providers. For both groups, the training varies widely in quality and extent. It is important that this multifaceted area is mapped and investigated, in order to improve safety for the citizens, and to facilitate cooperation between researchers and providers.
Even the definition, and also the provision of different types of CAM alter from country to country. To give an example: the provision of chiropractic in Scandinavia is very much a part of routine medical care, whereas in some countries it has historically been “outlawed”.
The aim of WP5 is to identify the different models of CAM provided by registered physicians and practitioners within European public health systems in order to describe the European situation in relation to other international perspectives. Also, WP5 will act as an evaluation platform providing vital information about the practice of CAM among certified physicians and practitioners in the EU.
Specifically, WP5 will review literature addressing the providers’ perspective of CAM use in Europe; how many providers offer CAM, which different CAM methods are provided. The WP5 members will also identify the health problems for which CAM is utilized, and we will describe the impact of research results on health care practice. Finally, it is important to explore how CAM research and the relevant evidence base are integrated into CAM practice.
A questionnaire will be designed by the WP5 members allowing to collect data in a systematic manner, identifying representatives / stakeholders and inviting them to cooperate with CAMbrella. WP5 will contact the relevant national body for each specific CAM method, identifying their areas of interest, training and requirements for the continuing registration. Later, a map of nationally based activities will be developed by WP5, informing the other WPs, as well as the public.
The overview provided by WP5 will inform relevant stakeholders (patients, providers and funders) and contribute substantially to the implementation of an informed European regulatory framework that will harmonise procedures and the provision of CAM therapies and products in EU member states.
The work in WP5 will be finished by the end of 2011.